Live Breaking News & Updates on Robert Motzer|Page 1

Stay updated with breaking news from Robert motzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma. ....

United States , San Francisco , Toni Choueiri , Dorothy Byrne , Paulv Viscuse , Robert Motzer , Nancy Kohlberg , Harvard Medical School , Genitourinary Tumors Multidisciplinary Clinic Center , Memorial Sloan Kettering Cancer Center , International Metastatic Renal Cell Carcinoma Database Consortium , Lank Center , Cancer Research Of The National Institute , Genitourinary Oncology Service , Genitourinary Oncology At Dana Farber Cancer Institute , University Of Virginia , National Clinical Trials Network , Cancers Symposium , Andrea Apolo , Bladder Cancer Section , Genitourinary Malignancies Branch , Bladder Cancer , Cancer Research , National Cancer Institute , Kidney Cancer , Dorothy Byrne Chair ,

A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS ....

Dana Farber Cancer Institute , United States , Memorial Sloan Kettering Cancer Center , New York , Tony Choueiri , Pedroc Barata , Robert Motzer , University Hospitals Seidman Cancer Center , Genitourinary Cancers Symposium ,

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo to be shared in a late-breaking oral presentation

Four-year data from CheckMate -9ER and. ....

San Francisco , United States , South Korea , Maria Teresa Bourlon , Robert Motzer , Bristol Myers Squibb , Samit Hirawat , Daniel Geynisman , Alex Chehrazi , Nizar Tannir , Saby George , Dana Rathkopf , Drug Administration , European Union , Exchange Commission , Drug Development , American Society Of Clinical Oncology , Ono Pharmaceutical Co , Company Opdivo , American Society , Clinical Oncology , Cancers Symposium , Bristol Myers , Prostate Cancer , Renal Cell Cancer , Renal Cell ,

Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab. ....

Elizabeth Plimack , Robert Motzer , Evolving Treatments , Advanced Renal Cell Carcinoma , Renal Cell Carcinoma , Metastatic Renal Cell Cancer , Dose Reduction , Adjuvant Therapy , Toxicity Management , Blood Pressure , Thyroid Toxicity , Liver Toxicity , Hand Foot Syndrome ,

Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria. ....

Elizabeth Plimack , Robert Motzer , Evolving Treatments , Advanced Renal Cell Carcinoma , Long Term Toxicities , Combination Lenvatinib , Renal Cell Carcinoma , Metastatic Renal Cell Cancer , Dose Reduction , Adjuvant Therapy , Toxicity Management , Blood Pressure , Thyroid Toxicity , Liver Toxicity , Hand Foot Syndrome ,